Large gap with delayed quotes
|
Last quote
05/09/2026
-
02:00:00
|
Bid
05/08/2026 -
21:59:59
|
Bid Volume |
Ask
05/08/2026 -
21:59:59
|
Ask Volume |
|---|---|---|---|---|
|
295.05
-0.86
(
-0.29% )
|
294.87
|
200 |
295.09
|
40 |
Analysis date: 05.05.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 13.05.2025.
Interest
Weak
Weak
Two stars since 17.04.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 14.04.2026 at a price of 339.41.
Evaluation
Undervalued
Undervalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately undervalued.
MT Tech Trend
Negative
Negative
The dividend-adjusted forty day technical trend is negative since 17.04.2026.
4wk Rel Perf
-15.84%
-15.84%
The four-week dividend-adjusted underperformance versus SP500 is 15.84%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 20.05.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.38%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.07%.
Mkt Cap in $bn
39.78
39.78
With a market capitalization >$8bn, ALNYLAM PHARMACEUTICALS is considered a large-cap stock.
G/PE Ratio
1.21
1.21
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
24.84
24.84
The estimated PE is for the year 2028.
LT Growth
29.97%
29.97%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
19
19
Over the last seven weeks, an average of 19 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
28
28
For 1% of index variation, the stock varies on average by 0.28%.
Correlation
0.09
0.09
Stock movements are totally independent of index variations.
Value at Risk
46.89
46.89
The value at risk is estimated at USD 46.89. The risk is therefore 15.57%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
13.12.2006
13.12.2006